Argenx Touts Positive Phase 3 Eye Disease Study Results

Argenx SE (NASDAQ:ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).It is an autoimmune disorder where antibodies disrupt nerve-muscle communication, causing variable, fatiguing weakness of eye muscles and eyelids (ptosis) and double vision (diplopia).The study met its primary endpoint, demonstrating statistically significant improvement in patient-reported outcomes.Argenx Says Vyvgart Improves Double Vis ...